



NeuroScientific

BIOPHARMACEUTICALS

5 March 2019

Company Update

Neuroscientific has successfully placed the shortfall from the recent rights issue that has raised in excess of \$290,000. Thank you to those that participated in the non-renounceable option entitlement enabling the company to be fully funded through to the end of Phase 1 trials.

I would like to bring to your attention a very significant development for NSB in the past month that has featured in 'Nature', 'The Economist' and the February 2019 issue of 'Fortune'. Alzheimer's research has pivoted towards a 'radical new approach' focused on the 'survival' of brain cells to combat degenerative neurological disease. This contrasts with the focus of research in the last decade for the removal of beta-amyloid plaque build-up in the brain that was believed to cause dementia. Many billions of dollars have been spent on that failed approach. Many billions of dollars more will now be spent on this new approach and NSB is already at the forefront. Whilst we have only recently listed on the ASX and are yet to make our mark in the global investment community, rest assured, that it is our goal for this year to embark on a series of national and international investor roadshows and prestigious international Alzheimer's conferences to raise awareness that NSB is to our knowledge, the only company in the world poised to commence human studies in this specific field of research.

Our lead compound, EmtinB is presently undergoing further animal studies in partnership with the Lions Eye Institute and Charles River Labs. Covance Labs are also completing preclinical safety and toxicology studies that will allow EmtinB to progress to human clinical trials in Q3 of this calendar year. NSB has also engaged Auspep Pty Ltd, a GMP accredited peptide manufacturing company to produce the EmtinB active pharmaceutical ingredient to support our ongoing pre-clinical and future clinical programs.

The search for an effective treatment of neurological diseases such as Alzheimer's is considered the 'holy grail' in drug research and is evidenced by much increased investment activity from blue chip US hedge funds and venture capital into the sector. NSB's novel approach to cell survival was considered 'radical' at the time of its listing mid-last year but now is likely to be considered mainstream by the scientific community as inevitably interest in this space intensifies. NSB's advantage, we're moving into human trials this year which is effectively 'light years' ahead of the competition. I am looking forward to raising awareness of our gem of a company and highly confident that our shareholders will benefit from this pursuit.

Warm regards

Brian Leedman

Chairman, NeuroScientific Biopharmaceuticals Limited

